Want to see GB:4BB full AI Analyst Report?
4BB Stock Chart & Stats
615.00 p
25.00 p(2.04%)
At close: 4:00 PM EST
615.00 p
25.00 p(2.04%)
Day’s Range― - ―
52-Week Range420.00 p - 1,033.00 p
Previous CloseN/A
Volume812.00
Average Volume (3M)999.00
Market Cap
£81.30M
Enterprise Value80.00M
Total Cash (Recent Filing)£17.80M
Total Debt (Recent Filing)£16.50M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding15,538,518
10 Day Avg. Volume230
30 Day Avg. Volume999
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.43
Price to Sales (P/S)56.33
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,400.00Price Target Upside127.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1
Revenue Forecast (FY)£2.60M
Bulls Say, Bears Say
Bulls Say
Core Supplier To Gene Therapy Value ChainSupplying plasmid and synthetic DNA as critical starting materials positions the company in a structural niche of gene therapy and mRNA supply chains. This creates durable, repeatable demand as customers progress from research to clinical and commercial phases, supporting long-term revenue potential if quality and capacity scale.
Product-level Pricing/value CapturePositive gross margins imply the business can charge for and deliver differentiated DNA products or efficient production. If fixed operating costs are controlled and volumes scale, these product-level margins offer a path to leverage revenue into improved operating profitability over the medium term despite current volatility.
Long-run Revenue Growth Off Small BaseHistorical revenue expansion from a small base shows commercial traction and customer adoption of DNA products and services. While 2025 saw a pullback, the multi-year growth trend indicates the company can scale sales as partner programs progress, supporting medium-term upside if recurring and larger GMP runs materialize.
Bears Say
Accelerating Cash BurnPersistent negative operating and free cash flow with accelerating burn reduces runway and increases reliance on external financing. That constrains the firm's ability to invest in capacity, sustain R&D or absorb customer timing variability, raising dilution and refinancing risk over the medium term if cash generation doesn't improve.
Deteriorating Capital StructureRising leverage and sharply reduced equity weaken financial flexibility and heighten refinancing risk. High debt-to-equity can limit strategic options, raise interest burden, and force equity raises under adverse terms, all of which can dilute shareholders and restrict investment in scale-up or quality infrastructure vital for long-term competitiveness.
Deep And Widening LossesSustained negative margins and growing losses impair the firm's ability to become self-sustaining. Without durable margin improvement or significant revenue scale, persistent losses exacerbate cash needs, reduce investor tolerance for dilution, and undermine prospects for reinvestment into capacity and quality systems needed for long-term customer contracts.
4basebio UK Societas News
4BB FAQ
What was 4basebio UK Societas’s price range in the past 12 months?
4basebio UK Societas lowest share price was 420.00 p and its highest was 1033.00 p in the past 12 months.
What is 4basebio UK Societas’s market cap?
4basebio UK Societas’s market cap is £81.30M.
When is 4basebio UK Societas’s upcoming earnings report date?
4basebio UK Societas’s upcoming earnings report date is Sep 25, 2026 which is in 72 days.
How were 4basebio UK Societas’s earnings last quarter?
4basebio UK Societas released its earnings results on May 20, 2026. The company reported -0.586 p earnings per share for the quarter, beating the consensus estimate of -0.59 p by 0.004 p.
Is 4basebio UK Societas overvalued?
According to Wall Street analysts 4basebio UK Societas’s price is currently Undervalued.
Does 4basebio UK Societas pay dividends?
4basebio UK Societas does not currently pay dividends.
What is 4basebio UK Societas’s EPS estimate?
4basebio UK Societas’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4basebio UK Societas have?
4basebio UK Societas has 15,538,518 shares outstanding.
What happened to 4basebio UK Societas’s price movement after its last earnings report?
4basebio UK Societas reported an EPS of -0.586 p in its last earnings report, beating expectations of -0.59 p. Following the earnings report the stock price went up 7.865%.
Which hedge fund is a major shareholder of 4basebio UK Societas?
Currently, no hedge funds are holding shares in GB:4BB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4basebio UK Societas Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£1,400.00 (127.64% Upside)
£1,400.00 (127.64% Upside)
Insider Transactions
Bought Shares
Worth £9.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.99%
12-Months-Change
Fundamentals
Return on Equity
-116.21%
Trailing 12-Months
Asset Growth
-33.93%
Trailing 12-Months
Company Description
4basebio UK Societas
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.
4BB Stock 12 Month Forecast
Average Price Target
1,400.00 p
▲(127.64% Upside)
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---